Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Merck was testing the injectable version of the world's biggest selling drug in a late stage trial of patients with a type of ...
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...